https://www.linkedin.com/posts/telixpharma_later-this-week-telix-...

https://www.linkedin.com/posts/telixpharma_later-this-week-telix-will-be-attending-activity-7191262309111980032-nMRX?utm_source=share&utm_medium=member_desktop


Later this week, Telix will be attending the largest gathering of urologists worldwide at the American Urological Association's 2024 Annual Meeting in San Antonio, Texas.The ProstACT GLOBAL Phase III study of TLX591, Telix’s first-in-class investigational PSMA-targeting radio antibody-drug conjugate therapy for prostate cancer, will be featured as an oral presentation, alongside a series of presentations on Telix’s approved PSMA-PET imaging agent, Illuccix®.Come meet the team at booth #631 to discuss Telix’s theranostic programs in urology and join the discussion on the future of kidney cancer detection and management, and PSMA imaging for the initial staging of prostate cancer through two thought leadership sessions at the AUA Product Theater (booth #1159). To learn more about Telix’s presence at AUA and to secure your seat at the theater visit: https://bit.ly/3WnY34q